Jamieson is pleased to announce that we have advised Antonio Parada and the management team of FairJourney Biologics on the recent investment by Partners Group. As part of the deal, it was agreed that FairJourney’s existing backer, GHO, will roll over a part of its investment alongside Partners Group and management.
FairJourney Biologics is a leading provider of antibody discovery and development services to the biopharmaceutical industry. The company specializes in delivering high-quality antibody solutions for therapeutic, diagnostic, and research purposes. With a strong focus on innovation and cutting-edge technology, FJB supports its clients in accelerating their drug development processes.
Stuart Coventry, Stephen Maxwell, Henry Balcerak & Adam Colley advised Antonio and the management team on their reinvestment into the new structure and the economic terms of the management equity program going forward.
